🔎 Trials Near Me

ホーム › アトピー性皮膚炎(湿疹) › カリフォルニア州

カリフォルニア州におけるアトピー性皮膚炎(湿疹)の臨床試験

カリフォルニア州内の拠点で、アトピー性皮膚炎(湿疹)に関する30件の研究が参加者を募集しています。

カリフォルニア州内の都市

公式研究テキスト(英語)

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

  • First OC Dermatology, Irvine
被験者募集中第1相健康なボランティア歓迎
18歳〜72歳 · 全性別 · 2026/09/29更新 · NCT06808477

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

  • Kern Research, Inc.- Site Number : 8400047, Bakersfield
  • Center for Dermatology Clinical Research- Site Number : 8400014, Fremont
  • Dermatology Research Associates - Los Angeles- Site Number : 8400020, Los Angeles
  • 他4件
被験者募集中観察研究
12歳以上 · 全性別 · 2026/09/29更新 · NCT07290803

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

  • Novartis Investigative Site, Fountain Valley
  • Novartis Investigative Site, Los Angeles
  • Novartis Investigative Site, Sacramento
  • 他2件
被験者募集中第2相
18歳〜100歳 · 全性別 · 2026/09/28更新 · NCT06947993

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

  • Enveda Investigative Site, Beverly Hills
  • Enveda Investigative Site, Fremont
  • Enveda Investigative Site, San Diego
  • 他3件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/25更新 · NCT07298395

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

  • Alliance Clinical West Hills (Focus Clinical Research), West Hills
被験者募集中第1相健康なボランティア歓迎
18歳〜65歳 · 全性別 · 2026/09/25更新 · NCT07527923

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

  • Investigational Drug Service - Rady Childrens Hospital-San Diego, San Diego
  • University of California, San Diego/ Rady Children's Hospital - San Diego, San Diego
被験者募集中第3相
2歳〜11歳 · 全性別 · 2026/09/25更新 · NCT06807281

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

  • Marvel Clinical Research, Huntington Beach
  • Metropolis Dermatology - DTLA, Los Angeles
  • Northridge Clinical Trials, Northridge
  • 他1件
被験者募集中第2相
18歳〜64歳 · 全性別 · 2026/09/25更新 · NCT07216027

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

  • Investigational Site, Fountain Valley
  • Investigational Site, Los Angeles
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07003425

The Impact of Dietary Salt on the Severity of Eczema

  • San Francisco VA Medical Center, San Francisco
  • UCSF Mt Zion Campus, San Francisco
被験者募集中第4相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/09/10更新 · NCT07447063

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

  • UCSF Mt Zion Campus, San Francisco
  • San Francisco VA Medical Center, San Francisco
被験者募集中第4相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/09/09更新 · NCT07487831

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

  • UCLA Division of Dermatology, Los Angeles
  • Dermatology Research Associate, Los Angeles
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07223697

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

  • Northridge Clinical Trials, Northridge
被験者募集中第3相
12歳以上 · 全性別 · 2026/09/04更新 · NCT07765888

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

  • Marvel Research, LLC, Huntington Beach
  • Metropolis Dermatology, Los Angeles
  • Dermatology Research Associates, Los Angeles
  • 他4件
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/08/28更新 · NCT07599813

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

  • Allergy and Asthma Medical Group and Research Center, San Diego
被験者募集中観察研究
12歳以上 · 全性別 · 2026/08/17更新 · NCT06899204

Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

  • Integrative Skin Science and Research, Sacramento
被験者募集中第4相
12歳以上 · 全性別 · 2026/08/13更新 · NCT07560618

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

  • Inmagene Site 1, Lancaster
  • Inmagene Site 23, Los Angeles
被験者募集中第2相
18歳〜74歳 · 全性別 · 2026/08/12更新 · NCT07037901

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

  • Enveda Investigative Site, Encinitas
  • Enveda Investigative Site, Los Angeles
  • Enveda Investigative Site, Northridge
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07643766

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

  • Stanford University School of Medicine /ID# 269622, Palo Alto
  • Integrative Skin Science and Research /ID# 265108, Sacramento
被験者募集中第3相
2歳〜11歳 · 全性別 · 2026/08/06更新 · NCT06461897

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

  • Anaheim Clinical Trials, LLC, Anaheim
  • TCR Medical Corporation, San Diego
被験者募集中第1相健康なボランティア歓迎
18歳〜70歳 · 全性別 · 2026/07/22更新 · NCT06564389

Sodium in the Skin and Atopic Dermatitis

  • San Francisco VA Medical Center, San Francisco
  • UCSF Mt Zion Campus, San Francisco
被験者募集中観察研究健康なボランティア歓迎
50歳以上 · 全性別 · 2026/07/14更新 · NCT06998446

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

  • Leo Pharma Investigational site, Palo Alto
  • Leo Pharma Investigational site, Sacramento
  • Leo Pharma Investigational site, San Diego
被験者募集中第3相
6 Months – 11 Years · 全性別 · 2026/07/07更新 · NCT06311682

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

  • Exalt Clinical Research /ID# 281611, Chula Vista
  • Private Practice - Dr. Tooraj Raoof /ID# 263849, Encino
  • First OC Dermatology /ID# 263349, Fountain Valley
  • 他8件
被験者募集中第3相
18歳〜63歳 · 全性別 · 2026/07/06更新 · NCT06389136

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

  • University of California, San Diego: Dermatology Clinical Trials Unit, San Diego
被験者募集中第1相
6歳以上 · 全性別 · 2026/07/02更新 · NCT06504160

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

  • First OC Dermatology, Fountain Valley
  • Center for Dermatology Clinical Research, Inc., Fremont
  • California Allergy and Asthma Medical Group, Los Angeles
  • 他1件
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/06/15更新 · NCT06397911

Molecular Signatures of Cutaneous Dupilumab Response

  • University of California, San Francisco, San Francisco
被験者募集中第4相
18歳以上 · 全性別 · 2026/06/04更新 · NCT05858619

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

  • Marvel Clinical Research, Huntington Beach
  • California Allergy and Asthma Medical Group, Los Angeles
  • University Dermatology Trials, INC., Newport Beach
  • 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/04更新 · NCT05995964

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

  • Galderma Investigational Site - 7074, Corona
  • Galderma Investigational Site 8636, Fountain Valley
  • Galderma Investigational Site 8224, Fremont
  • 他4件
被験者募集中観察研究
12歳以上 · 全性別 · 2026/03/13更新 · NCT06988605

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

  • Corvus Clinical Trials, South San Francisco
被験者募集中第2相
18歳以上 · 全性別 · 2026/03/05更新 · NCT07441395

Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT

  • University of California San Diego (UCSD), La Jolla
被験者募集中観察研究
全年齢 · 女性 · 2025/01/28更新 · NCT05938478

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。